Melomanes Fall School

We are happy to announce our School of nanomedicine and cancer immunotherapy. It will take place on Tuesday 24th and Wednesday 25th October 2023, at Åbo Akademi University in Turku (Finland).

Our Melomanes researchers, together with invited local partners, will provide an overview of their multidisciplinary cutting-edge research. Discover how nanomedicine and novel immunotherapies are opening new roads for cancer treatments!

This event is aimed at early-stage researchers interested in getting a broad overview of these fields of research.
It is open to researchers outside Melomanes network.

Information about registration, including registration fees, will be provided by September 2023 on the website School of nanomedicine and cancer immunotherapy.

Speakers

(Provisional talk titles)

• Dr. Yassen Abbas, CN Bio (United Kingdom): Development of organ-on-chip for the investigation of cancer treatments
• Prof. Khuloud Al-Jamal, King’s College London (United Kingdom): Therapeutic and diagnosis applications of nanomaterials
• Dr. Belén Ballesteros, Institut Català de Nanociència i Nanotecnologia (Spain): Advanced electron microscopy techniques for nanoscience
• Prof. Davide Bonifazi, University of Vienna (Austria): Functional organic architectures for nanomedicine
• Dr. Emmanuel Donnadieu, Institut Cochin (France): Targeting the tumor microenvironment to improve T cell-based immunotherapies
• Dr. Lorena García Hevia, IDIVAL (Spain): Nanomaterials for cancer treatments
• Dr. Florence Gazeau, CNRS MSC Med (France): Magnetic hyperthermia and photothermal treatments in nanomedicine
• Prof. Roland Grafström, Misvik (Finland): Assessment of cellular mode-of-actions by toxicogenomics space modeling
• Dr. Roland Hischier, Empa (Switzerland): Life cycle assessment in nanomedicine
• Dr. Jianwei Li, University of Turku (Finland): Molecular systems engineering for nanomedicine
• Dr. Cécilia Ménard-Moyon, CNRS I2CT (France): Multifunctionalisation of nanoparticles for nanomedicine
• Dr. Michiel van Oudheusden, Vrije Universiteit Amsterdam (Netherlands): Responsible modulation of nanotechnology
• Prof. Jessica Rosenholm, Åbo Akademi University (Finland): Multifunctional hybrid and composite nanostructures for drug delivery and imaging
• Dr. Gerard Tobias, Institut Català de Nanociència i Nanotecnologia (Spain): Radioactive nanomaterials for the diagnosis and treatment of cancer
• Prof. Sébastien Wälchli, Oslo University Hospital (Norway): New perspectives of engineered T-cells in cancer therapy
  
• Prof. Hongbo Zhang, Åbo Akademi University (Finland): Functional materials for biomedical applications and clinical translation
• to be confirmed, Orion (Finland): AI-powered drug delivery development

About Melanomanes

MELANOMANES has received funding from the European Union’s Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant. MELOMANES aims to train 12 doctoral researchers for the development of a combined therapy exploiting the properties of magnetic nanoparticles to induce damage on the tumor microenvironment by magnetic and optic hyperthermia in order to facilitate the infiltration of CAR-T cells.